Information:

My group is assigned to a drug target that has been previously adopted in successful drug design commercially. Our project will require a summary of information to be generated on the development of the drug and include preclinical and clinical sections, presented as a case study.

Our drug target is: **Romidepsin** – lymphoma

My part is to the Preclinical Development.

- **In vitro (600 words)**

- Provide detailed information on your drug and drug target. This may include information related to proof of concept or target validation studies, or high throughput screening for initial compound leads
- It may include aspects of medicinal chemistry, highlighting the evolution of the compound structure from initial leads
- Include chemical representations of your drug (2-D and/or 3-D) and any derivatives, including any novel aspects to the medicinal chemistry if appropriate (e.g. challenging syntheses steps)
- Any in silico (molecular modelling) studies can also go in here
- You may also include any in vitro PK (ADME) or safety and toxicology data

- **In vivo (600 words)**

- Include any pharmacokinetic (ADME) information and any adverse effects (safety profiling) from in vivo (animal) studies
- Try to summarise or describe the PK profile rather than just listing parameters (e.g. describe if its bioavailability or half-life is low or high)
- i.e. highlight or emphasize notable PK characteristics (high bioavailability or low clearance, enterohepatic recirculation etc)
- This section may include animal disease models where your drug was trialed as proof of preclinical efficacy

➔ Include diagrams, figures and tables etc.